• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自动化凝血和纤维蛋白溶解激活标志物的测量:在新型冠状病毒病 2019(COVID-19)患者中的结局。

Automated measurement of coagulation and fibrinolytic activation markers: Outcomes in coronavirus disease 2019 (COVID-19) patients.

机构信息

Specialist Laboratory Medicine, St James University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Haemostasis Research Unit, University College London, London, UK.

出版信息

Int J Lab Hematol. 2022 Oct;44(5):817-822. doi: 10.1111/ijlh.13855. Epub 2022 Apr 22.

DOI:10.1111/ijlh.13855
PMID:35451557
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9111592/
Abstract

BACKGROUND

Severe coronavirus disease 2019 (COVID-19) is characterized by marked hypoxaemia and lung oedema, often accompanied by disordered blood coagulation and fibrinolytic systems, endothelial damage and intravascular fibrin deposition.

PATIENTS/METHODS: We present a retrospective observational study of 104 patients admitted to hospital with COVID-19. Plasma samples were collected within 72 h of admission. In addition to routine coagulation and haematology testing, soluble thrombomodulin (sTM), thrombin-antithrombin (TAT), tissue plasminogen activator-plasminogen activator inhibitor 1 complex (tPAI-C) and plasmin-α2 antiplasmin complex (PIC) were performed by automated chemiluminescent enzyme immunoassays.

RESULTS

Significantly higher levels of D-dimer, TAT, sTM and tPAI-C were observed in non-survivors compared to survivors. To confirm which parameters were independent risk factors for mortality, multiple logistic regression was performed on D-dimer, TAT. sTM, tPAI-C and PIC data. Only increasing sTM was significantly associated with mortality, with an odds ratio of 1.065 for each 1.0 TU/mL increment (95% CI 1.025-1.115).

CONCLUSIONS

Of the haemostatic variables measured, sTM, which can be rapidly assayed, is the best independent predictor of mortality in patients hospitalized with COVID-19, and this suggests that endothelial dysfunction plays an important role in disease progression.

摘要

背景

严重的 2019 年冠状病毒病(COVID-19)的特征是明显的低氧血症和肺水肿,常伴有凝血和纤维蛋白溶解系统紊乱、内皮损伤和血管内纤维蛋白沉积。

患者/方法:我们报告了 104 例 COVID-19 住院患者的回顾性观察性研究。在入院后 72 小时内采集血浆样本。除了常规凝血和血液学检测外,还通过自动化化学发光酶免疫测定法检测可溶性血栓调节蛋白(sTM)、凝血酶-抗凝血酶(TAT)、组织纤溶酶原激活物-纤溶酶原激活物抑制剂 1 复合物(tPAI-C)和纤溶酶-α2 抗纤溶酶复合物(PIC)。

结果

与幸存者相比,非幸存者的 D-二聚体、TAT、sTM 和 tPAI-C 水平显著升高。为了确认哪些参数是死亡率的独立危险因素,对 D-二聚体、TAT、sTM、tPAI-C 和 PIC 数据进行了多变量逻辑回归分析。只有 sTM 的增加与死亡率显著相关,每增加 1.0 TU/mL,比值比为 1.065(95%CI 1.025-1.115)。

结论

在所测量的止血变量中,sTM 是 COVID-19 住院患者死亡率的最佳独立预测因子,这表明内皮功能障碍在疾病进展中起重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50cc/9111592/062c6c7ad0a3/IJLH-9999-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50cc/9111592/062c6c7ad0a3/IJLH-9999-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50cc/9111592/062c6c7ad0a3/IJLH-9999-0-g001.jpg

相似文献

1
Automated measurement of coagulation and fibrinolytic activation markers: Outcomes in coronavirus disease 2019 (COVID-19) patients.自动化凝血和纤维蛋白溶解激活标志物的测量:在新型冠状病毒病 2019(COVID-19)患者中的结局。
Int J Lab Hematol. 2022 Oct;44(5):817-822. doi: 10.1111/ijlh.13855. Epub 2022 Apr 22.
2
Coagulation and Fibrinolysis Biomarkers as Potential Indicators for the Diagnosis and Classification of Ovarian Hyperstimulation Syndrome.凝血和纤溶生物标志物作为卵巢过度刺激综合征诊断和分类的潜在指标
Front Med (Lausanne). 2021 Aug 25;8:720342. doi: 10.3389/fmed.2021.720342. eCollection 2021.
3
Identification of soluble thrombomodulin and tissue plasminogen activator-inhibitor complex as biomarkers for prognosis and early evaluation of septic shock and sepsis-induced disseminated intravascular coagulation.鉴定可溶性血栓调节蛋白和组织型纤溶酶原激活物抑制剂复合物作为脓毒性休克和脓毒症诱发弥散性血管内凝血的预后和早期评估的生物标志物。
Ann Palliat Med. 2021 Oct;10(10):10170-10184. doi: 10.21037/apm-21-2222. Epub 2021 Sep 14.
4
Changes of new coagulation markers in healthy pregnant women and establishment of reference intervals in Changsha.长沙地区健康孕妇新凝血标志物的变化及参考区间的建立。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Apr 28;47(4):469-478. doi: 10.11817/j.issn.1672-7347.2022.210536.
5
Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and sTM in disseminated intravascular coagulation: A multi-center prospective observational study.评估 TAT、PIC、tPAIC 和 sTM 在弥散性血管内凝血中的联合诊断价值:一项多中心前瞻性观察研究。
Thromb Res. 2019 Jan;173:20-26. doi: 10.1016/j.thromres.2018.11.010. Epub 2018 Nov 13.
6
Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.口服避孕药引起的血液凝固和纤维蛋白溶解变化以及雌激素对内皮细胞作用的研究。
Ann Hematol. 1993 Jul;67(1):33-6. doi: 10.1007/BF01709663.
7
Clinical Efficacy of Soluble Thrombomodulin, Tissue Plasminogen Activator Inhibitor complex, Thrombin-Antithrombin complex,α2-Plasmininhibitor-Plasmin complex in Pediatric Sepsis.可溶性血栓调节蛋白、组织型纤溶酶原激活物抑制剂复合物、凝血酶-抗凝血酶复合物、α2-抗纤溶酶-纤溶酶复合物在儿科脓毒症中的临床疗效。
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221102929. doi: 10.1177/10760296221102929.
8
Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.弥散性血管内凝血相关心搏骤停后综合征患者的凝血-纤溶变化——纤溶抑制和纤溶激活不足导致器官功能障碍。
Thromb Res. 2013 Jul;132(1):e64-9. doi: 10.1016/j.thromres.2013.05.010. Epub 2013 May 30.
9
Diagnostic and Prognostic Value of TAT, PIC, TM, and t-PAIC in Malignant Tumor Patients With Venous Thrombosis.凝血酶-抗凝血酶复合物、纤溶酶-α2纤溶酶抑制物复合物、血栓调节蛋白及纤溶酶原激活物抑制物-1在恶性肿瘤合并静脉血栓患者中的诊断及预后价值
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620971041. doi: 10.1177/1076029620971041.
10
Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study.凝血酶 - 抗凝血酶复合物、纤溶酶原激活物抑制剂 -1 及蛋白 C 活性联合检测用于脓毒症初期严重凝血病的早期识别:一项前瞻性观察研究
Crit Care. 2014 Jan 13;18(1):R13. doi: 10.1186/cc13190.

引用本文的文献

1
Time to maximum amplitude of thromboelastography can predict mortality in patients with severe COVID-19: a retrospective observational study.血栓弹力图最大振幅时间可预测重症新型冠状病毒肺炎患者的死亡率:一项回顾性观察研究
Front Med (Lausanne). 2024 May 2;11:1356283. doi: 10.3389/fmed.2024.1356283. eCollection 2024.
2
Variation in presepsin and thrombomodulin levels for predicting COVID-19 mortality.降钙素原和血栓调节蛋白水平的变化预测 COVID-19 死亡率。
Sci Rep. 2023 Dec 6;13(1):21493. doi: 10.1038/s41598-023-48633-0.
3
Antithrombin as Therapeutic Intervention against Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation: Lessons Learned from COVID-19-Associated Coagulopathy.

本文引用的文献

1
HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study.羟甲基戊二酰辅酶 A 还原酶抑制剂与瑞典斯德哥尔摩地区 COVID-19 死亡率:一项基于登记的队列研究。
PLoS Med. 2021 Oct 14;18(10):e1003820. doi: 10.1371/journal.pmed.1003820. eCollection 2021 Oct.
2
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.COVID-19 住院高危患者中治疗剂量肝素与标准预防剂量或中剂量肝素预防血栓的疗效和安全性:HEP-COVID 随机临床试验。
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203.
3
抗凝血酶作为治疗脓毒症相关性凝血病和弥散性血管内凝血的干预手段:从 COVID-19 相关凝血病中吸取的教训。
Int J Mol Sci. 2022 Oct 18;23(20):12474. doi: 10.3390/ijms232012474.
Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection.
新型冠状病毒2019感染中肺组织因子上调、血栓调节蛋白缺失与免疫性血栓形成
EClinicalMedicine. 2021 Sep;39:101069. doi: 10.1016/j.eclinm.2021.101069. Epub 2021 Aug 6.
4
Persistent endotheliopathy in the pathogenesis of long COVID syndrome.长新冠综合征发病机制中的持续内皮病变。
J Thromb Haemost. 2021 Oct;19(10):2546-2553. doi: 10.1111/jth.15490. Epub 2021 Sep 12.
5
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.新冠肺炎危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4.
6
Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis.COVID-19 患者内皮功能障碍及结局的生物标志物:系统评价和荟萃分析。
Microvasc Res. 2021 Nov;138:104224. doi: 10.1016/j.mvr.2021.104224. Epub 2021 Jul 15.
7
A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN-6500 haemostasis analyser.在希森美康 CN-6500 止血分析仪上评估化学发光酶免疫分析的性能。
Int J Lab Hematol. 2021 Dec;43(6):1593-1598. doi: 10.1111/ijlh.13656. Epub 2021 Jul 12.
8
Endothelium Activation Markers in Severe Hospitalized COVID-19 Patients: Role in Mortality Risk Prediction.重症住院 COVID-19 患者的内皮激活标志物:在死亡风险预测中的作用
TH Open. 2021 Jul 4;5(3):e253-e263. doi: 10.1055/s-0041-1731711. eCollection 2021 Jul.
9
Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes.COVID-19 和脓毒症综合征的血管内皮病中的独特生物标志物特征。
Shock. 2022 Jan 1;57(1):95-105. doi: 10.1097/SHK.0000000000001823.
10
Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study.COVID-19 危重症患者的凝血、血管内皮功能和纤溶生物标志物:一项单中心前瞻性纵向研究。
J Thromb Haemost. 2021 Jun;19(6):1546-1557. doi: 10.1111/jth.15327. Epub 2021 May 1.